KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - Other
Ratios

Bristol Myers Squibb (BMY) Leases (2019 - 2025)

Bristol Myers Squibb (BMY) has disclosed Leases for 7 consecutive years, with $1.6 billion as the latest value for Q4 2025.

  • On a quarterly basis, Leases rose 29.25% to $1.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.6 billion, a 29.25% increase, with the full-year FY2025 number at $1.6 billion, up 29.25% from a year prior.
  • Leases was $1.6 billion for Q4 2025 at Bristol Myers Squibb, down from $1.6 billion in the prior quarter.
  • In the past five years, Leases ranged from a high of $1.6 billion in Q3 2025 to a low of $840.0 million in Q2 2022.
  • A 5-year average of $1.2 billion and a median of $1.2 billion in 2023 define the central range for Leases.
  • Peak YoY movement for Leases: fell 16.5% in 2022, then soared 54.81% in 2023.
  • Bristol Myers Squibb's Leases stood at $919.0 million in 2021, then soared by 32.75% to $1.2 billion in 2022, then grew by 13.93% to $1.4 billion in 2023, then fell by 11.94% to $1.2 billion in 2024, then increased by 29.25% to $1.6 billion in 2025.
  • Per Business Quant, the three most recent readings for BMY's Leases are $1.6 billion (Q4 2025), $1.6 billion (Q3 2025), and $1.3 billion (Q2 2025).